Can pharma sustain the rally? Chakri Lokapriya answers
“There is a move towards more complex generics which are higher margin and are subject to less price erosion in the US and also in the advanced markets. The US has traditionally been stronger pricing wise versus Europe. Against this whole backdrop, Lupin and Cipla because of the move towards complex generics, look to be positioned well.”